Stocks Industrials PACB
NASDAQ · IndustrialsPacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California, Inc. brought in $159.3M of revenue over the twelve months to June 30, 2026, up 2.0% from a year earlier. It posted a net loss of $131.4M. In fiscal 2025 capital spending exceeded operating cash flow by $113.9M. At June 30, 2026 it held $61M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Pacific Biosciences of California, Inc. does
Pacific Biosciences of California, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker PACB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $160M | -$546.4M | -$1.82 | -$113.9M |
| 2024 | $154M | -$309.9M | -$1.59 | -$212.2M |
| 2023 | $200.5M | -$306.7M | -$1.21 | -$268M |
| 2022 | $128.3M | -$314.2M | -$1.40 | -$280M |
| 2021 | $130.5M | -$181.2M | -$0.89 | -$117.1M |
| 2020 | $78.9M | $29.4M | $0.17 | $18.5M |
Latest SEC filings
What Pacific Biosciences of California, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 9, 2026
- June 4, 2026
- May 27, 2026
- May 22, 2026Additional proxy material DEFA14A
- May 8, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
Questions about PACB
What does Pacific Biosciences of California, Inc. do?
Pacific Biosciences of California, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker PACB.
Is Pacific Biosciences of California, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $131.4M on revenue of $159.3M.
How much revenue does Pacific Biosciences of California, Inc. make?
Over the twelve months to June 30, 2026 Pacific Biosciences of California, Inc. reported revenue of $159.3M. That is 2.0% more than a year earlier.
When did Pacific Biosciences of California, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
Similar companies
Follow PACB
Get an email when Pacific Biosciences of California, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PACB: get an email when it filesWhere the numbers come from
Financial figures are the values Pacific Biosciences of California, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.